Fibrate therapy and renal function
The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
Fibrates are a class of lipid-lowering medications primarily used as second-line agents behind statins. The adverse-effect profile of fibrates has been marked by a puzzling yet reversible rise in serum creatinine values with their use. It is not known whether this finding represents a true change in renal function. One proposed explanation for this phenomenon is that fibrates increase the production of creatinine, in which case a rise in serum creatinine values would not represent a true deterioration in renal function. An alternative theory is that fibrates reduce the production of vasodilatory prostaglandins, which would lead to a true change in renal function in patients who experience a rise in serum creatinine values. Routine serum creatinine monitoring is advisable in fibrate-treated patients, particularly in those with preexisting renal disease. A 30% increase in serum creatinine values in the absence of other causes of serum creatinine change warrants discontinuation of fibrate therapy. Serum creatinine values can take several weeks to return to their baseline values following discontinuation of a fibrate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its mechanism may involve renal hemodynamic changes or an increased creatinine release by muscle.30”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [30]
Citations
Cites
Serum Creatinine as an Index of Renal Function: New Insights into Old Concepts
Perrone, R. D., Madias, N. E., & Levey, A. S. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.10.1933 · Cited by 1,581 · cited 1×
“These factors include age, gender, ethnicity, body size, diet, certain drugs, and laboratory analytical methods [ 27 ].”
MethodKrey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.779 · Cited by 1,221 · cited 1×
“This has not been the case and, if anything, fi brate therapy decreases the rate of new-onset microalbuminuria in type 2 diabetes, and urinary albumin excretion is either unchanged or falls slightly in individuals who are already microalbuminuric/ proteinuric [4,9,21, 36 ].”
BackgroundSafety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 1×
“To date, it is unclear as to whether there are any long-term renal implications to this phenomenon and whether this is related to PPARα [ 42 ].”
BackgroundAnsquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264 · cited 2×
“In general, fi brate therapy is well tolerated and has a low frequency of adverse effects [4, 9 ,10].”
BackgroundBezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Managing Dyslipidemia in Chronic Kidney Disease
Harper, C. R., & Jacobson, T. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.025 · Cited by 204
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186 · cited 5×
“Creatinine production per se was not measured in these studies and a plausible theory for how a fi brate would increase overall creatinine production was not offered [ 15 ].”
BackgroundMethodInfluentialFibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.12.1993 · Cited by 163 · cited 7×
“The increase in serum creatinine with fi brates has been observed in patients with normal renal function [2,5– 10,11••,12–18,25], in patients with renal failure [18,32], and in transplant recipients [18,19, 24 ,26,33], and it is seen with doses as low as 67 mg/d [16].”
BackgroundInfluential
Cited by
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Martín, J. E. S., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.07.010 · Cited by 206
Metadata
- Authors
- Sica, D. A.
- Affiliations
- Virginia Commonwealth University (US)
- Corresponding author
- Sica, Domenic A.
- Venue
- Current Atherosclerosis Reports
- Published
- 2009-08-01
- Volume
- 11
- Issue
- 5
- Pages
- 338-342
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W1988933322
- Cited by
- 33
- References
- 45
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 4 · 2016: 2 · 2014: 1 · 2013: 1 · 2012: 3
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Atherosclerosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- fibrates, renal function, serum creatinine, prostaglandins, drug-induced nephrotoxicity, lipid-lowering therapy, statins, creatinine monitoring, drug discontinuation
- MeSH terms
- Animals, Clofibric Acid, Creatinine, Glomerular Filtration Rate, Humans, Kidney, Treatment Outcome, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrate therapy and renal function. https://app.cochat.ai/papers/10.1007/s11883-009-0051-5
- The paper
- Sica, D. A. (2009). Fibrate therapy and renal function. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-009-0051-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.